Guides et références
Prevention in Hand: For Patients
The College of Family Physicians of Canada, in partnership with the Public Health Agency of Canada, have collaborated on the development of Phase II of the Prevention in Hand initiative. This user-friendly website and mobile application are a valuable health care resource for health professionals and public alike to easily access current and accurate information about the prevention of chronic diseases.
Prevention in Hand: For Practitioners
The College of Family Physicians of Canada, in partnership with the Public Health Agency of Canada, have collaborated on the development of Phase II of the Prevention in Hand initiative. This user-friendly website and mobile application are a valuable health care resource for health professionals and public alike to easily access current and accurate information about the prevention of chronic diseases.
Recommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) : vaccin nonavalent contre le VPH et précisions sur les intervalles minimums entre les doses dans le calendrier d'immunisation contre le VPH
En février 2015, un vaccin nonavalent contre le virus du papillome humain a été autorisé au Canada. La présente déclaration vise à résumer les renseignements sur ce vaccin et à fournir des recommandations fondées sur des données probantes sur son utilisation dans le contexte des recommandations pour tous les vaccins contre le VPH actuellement autorisés au Canada. En outre, cette déclaration précise les intervalles minimums entre les doses des vaccins contre le VPH pour les calendriers de vaccination contre le VPH vaccination contre le VPH à deux ou à trois doses.
Recommandations sur l'utilisation du vaccin antirotavirus chez les nourrissons : Document de principes
Le présent document de principes vise à fournir des recommandations sur l'utilisation du vaccin antirotavirus pour protéger les nourrissons du Canada. Il résume l'information sur la maladie clinique et son épidémiologie, ainsi que sur l'innocuité et l'efficacité des vaccins antirotavirus actuellement homologués pour prévenir les infections à rotavirus au Canada. La vaccination antirotavirus systématique, recommandée pour les nourrissons, est financée par le gouvernement de la plupart des provinces et des territoires. Le présent document de principes remplace celui qui a été publié en 2010.
Recommendations for the use of rotavirus vaccines in infants: Position Statement
The purpose of the present statement is to provide recommendations for the use of rotavirus vaccine to protect infants in Canada. It summarizes information on clinical disease and epidemiology, as well as on the safety and efficacy of rotavirus vaccines currently licensed for the prevention of rotavirus disease in Canada. Routine rotavirus vaccination is recommended for infants and is publically funded in most provinces and territories. This statement replaces a previous rotavirus statement published in 2010.
Refrigerator and Freezer Vaccine Storage Guidelines
Illustrates safe vaccine storage and vaccine refrigerator and freezer maintenance.
Statement on Rotavirus Vaccines and Intussusception: An Advisory Committee Statement (ACS) Update
Highlights key information for immunization providers. Although there is no evidence that children who have a history of intussusception are at a higher risk of another intussusception after receiving RV vaccine, as a precaution, infants with a history of intussusception should not be given RV vaccine.
Update on Measles-Mumps-Rubella-Varicella Vaccine and Febrile Seizures: An Advisory Committee Statement (ACS)
Highlights key information for immunization providers.
Update on the Recommended use of Hepatitis A Vaccine
This statement serves as an update to previous statements and will provide the evidence used to determine the optimal timing of immunization with a HA containing vaccine by providing a review of the evidence on the immunogenicity and safety of HA vaccine when administered to infants from 6 to 12 months of age and making recommendations for the immunization of individuals in this age group; reviewing evidence pertaining to the administration of HA vaccine to individuals with non-malignant hematologic disorders; and reviewing evidence pertaining to post exposure prophylaxis (PEP) in individuals with chronic liver disease and adults over 50 years of age.
Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older Interim Recommendation
The objective of this Statement Update is to provide evidence and interim recommendations for the use of PNEU-C-13 in immunocompetent adults over 65 years of age and to allow informed decision making in cases when PNEU-C-13 is being considered on an individual basis for use in this age group.